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Abstract 31 
Background Reduced left ventricular ejection fraction (LVEF) after acute myocardial 32 
infarction (MI) increases risk of cardiovascular (CV) hospitalizations but evidence regarding 33 
its association with non CV outcome is scarce. We investigated the association between 34 
LVEF and adjudicated cause-specific hospitalizations following MI complicated with low 35 
LVEF or overt heart failure (HF). 36 
 37 
Methods In an individual patient data meta-analysis of 19,740 patients from three large 38 
randomized trials, Fine and Grey competing risk modelling was performed to study the 39 
association between LVEF and hospitalization types. 40 
 41 
Results The most common cause of hospitalization was non CV (n = 2,368 for HF, n = 1,554 42 
for MI, and n = 3,703 for non CV). All types of hospitalizations significantly increased with 43 
decreasing LVEF. The absolute risk increase associated with LVEF <25% (vs LVEF >35%) 44 
was 15.5% (95% confidence interval [CI] 13.4-17.5) for HF, 4.7% (95% CI 3.0-6.4) for MI, 45 
and 10.4% (95% CI 8.0-12.8) for non CV hospitalization. On a relative scale, after adjusting 46 
for confounders, each 5-point decrease in LVEF was associated with an increased risk of HF 47 
(hazard ratio [HR] 1.15, 95% CI 1.12-1.18), MI (HR 1.06, 95% CI 1.03-1.10), and non CV 48 
hospitalization (HR 1.03, 95% CI 1.01-1.05). 49 
 50 
Conclusions In a high-risk population with complicated acute MI, the absolute risk increase 51 
in non CV hospitalizations associated with LVEF <25% was 2/3 of the absolute risk increase 52 
in HF hospitalizations and twice the absolute risk increase in MI hospitalizations. LVEF was 53 
an independent predictor of all types of hospitalization and appears as an integrative marker 54 
of sicker patient status.  55 
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Abbreviations 58 
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SD Standard deviation 69 
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Introduction 70 
Despite considerable advance in prevention and treatment of cardiovascular (CV) 71 
disease over the past decades, acute myocardial infarction (MI) continues to be a 72 
major cause of morbidity and mortality worldwide.1 An area with potential 73 
improvement of care lies in mitigating the number of MI patients readmitted to 74 
hospital in the period following their event.2 Furthermore, the challenge is 75 
compounded by the fact that a significant proportion of such hospitalizations may be 76 
caused by other conditions conceivably not directly linked to the prior MI event.3 77 
Patients with heart failure (HF) or left ventricular (LV) dysfunction after acute MI are 78 
at high risk of subsequent hospitalization.4,5 Thus, identifying prognostic factors for 79 
these events may reduce morbidity and healthcare expenditure. Low LV ejection 80 
fraction (LVEF) is an established predictor of adverse outcome after MI, but its 81 
ability to forecast cause-specific hospitalization in a high-risk population is less well 82 
defined.6-8 As well, while the risk of non CV related outcomes has been investigated 83 
quite extensively in the field of HF and particularly in HF with preserved LVEF, data 84 
for such endpoints following complicated MI are scarce.9,10 On this background, the 85 
present study aimed to investigate the association between LVEF and adjudicated 86 
cause-specific hospitalizations for HF, MI, and non CV causes in patients at high risk 87 
for hospitalizations following complicated acute MI. 88 
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Methods 89 
The High-Risk Myocardial Infarction Database Initiative 90 
The High-Risk MI Database Initiative has been described in detail previously.11 In 91 
brief, it conformed a large-scale database by merging individual patient data (IPD) 92 
from several double-blind, randomized, placebo-controlled trials that evaluated 93 
pharmacological intervention after acute MI. All subjects had signs of HF, evidence 94 
of LV dysfunction, or both of these characteristics (n = 28,771). These were enrolled 95 
between 12 hours and 21 days after the index acute MI and followed for a mean of 2,7 96 
years. The main aims of the initiative were to define the prognostic profile of a high-97 
risk population with acute MI, explore important subgroups, and estimate event rates 98 
based on baseline demographics.11 The data used in the present study stem from three 99 
of the trials; the Carvedilol Post-Infarct Survival Control in LV dysfunction 100 
(CAPRICORN) trial (n = 1959), the Eplerenone Post Acute Myocardial Infarction 101 
Heart Failure Efficacy and Survival Study (EPHESUS) trial (n = 6632), and the 102 
Valsartan in Acute Myocardial Infarction (VALIANT) trial (n = 14,703). Their 103 
rationale, design, inclusion and exclusion criteria, definition of endpoints, and results 104 
have been published previously.12-17 The trials were conducted in accordance with the 105 
Declaration of Helsinki and were approved by ethics committees. All patients signed 106 
informed consents.  107 
The authors are solely responsible for the design and conduct of this study, all 108 
study analyses, the drafting and editing of the paper and its final contents. No 109 
extramural funding was used to support this work. 110 
 111 
Baseline data and evaluation of left ventricular function 112 
Baseline characteristics at the time of acute MI were registered, including 113 
demographics, past history, clinical observations, use of medications, and results of 114 
relevant blood tests. Patients were at each site per protocol assessed for symptoms and 115 
signs of HF and LVEF was determined by echocardiography, contrast 116 
ventriculography, or radionucleotide ventriculography. 117 
 118 
Clinical events 119 
Clinical events that occurred during follow-up were classified, including subtypes of 120 
CV hospitalization. Thus, HF and MI hospitalizations could be extracted as individual 121 
endpoints from the database. Non CV hospitalizations were defined as 122 
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hospitalizations due to other than predefined CV causes. All cause-specific events 123 
were by design adjudicated by independent endpoint committees. 124 
 125 
Statistical analysis 126 
Continuous variables are described as mean ± standard deviation (SD) or median 127 
(quartiles 1-3), and categorical variables are reported as frequencies (percentages).  128 
We compared baseline characteristics stratified by LVEF categories by using 129 
univariable analysis of variance for continuous variables and chi-square tests for 130 
categorical variables. We also compared LVEF groups by calculating absolute 131 
standardized mean difference. While there is no clear consensus as to what threshold 132 
can be taken to indicate the presence of imbalance, some authors have suggested that 133 
a standardized difference in excess of 0.10 may be indicative of meaningful 134 
imbalance in a covariate between two groups.18  135 
The Kaplan Meier method was used to assess risk for each outcome according 136 
to LVEF categories and event curves were generated. The risk differences at one year 137 
and two years with confidence intervals (CI) at 95%, between each of the two first 138 
groups (LVEF <25%, LVEF 25-35%) and the last group (LVEF >35%), are also 139 
provided. The relationship between LVEF (continuous per 5-point decrease or 140 
categorized (<25%, 25-35%, and >35%)) and events (HF hospitalization, MI 141 
hospitalization, and non CV hospitalization) were subsequently tested in Fine and 142 
Gray competing risk models with death as competing event. Model 1 included 143 
demographic characteristics (age and gender), model 2 included variables in model 1 144 
and clinical characteristics (Killip class, systolic blood pressure), comorbidities 145 
(diabetes, hypertension, renal insufficiency, chronic obstructive pulmonary disease, 146 
and peripheral artery disease), and medication (beta-blockers, angiotensin-converting 147 
enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARB), diuretics), and 148 
model 3 included variables in model 2 and estimated glomerular filtration rate. 149 
Hazard ratios (HR) and 95% CIs for time to event are reported. We also performed an 150 
exploratory assessment of the discriminative value of LVEF by testing the increase 151 
Harrell's c-index and continuous net reclassification improvement at one year. The 152 
continuous net reclassification improvement method developed by Uno and 153 
implemented in the survIDINRI package of the R software was used.19 154 
Statistical analyses were performed in SAS version 9.3 (SAS Institute Inc., 155 
Cary, North Carolina, USA) and R software (the R foundation for Statistical 156 
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Computing). Relevant methodological assumptions were verified, including pairwise 157 
interaction and collinearity, log-linearity, and proportionality of hazards. A p-value 158 
<0.05 was regarded statistically significant, and all hypothesis testing was two-tailed. 159 
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Results 160 
19,740 patients were included with a mean follow-up of 702 ± 337 days, during 161 
which 13,023 hospitalizations occurred. The most frequent cause of hospitalization 162 
was non CV (n = 3,703) followed by HF (n = 2,368) and MI (n = 1,554). 163 
 164 
Baseline characteristics 165 
Relevant baseline characteristics according to LVEF categories have been published 166 
previously and are presented in Table 1.20 The subjects in the lower LVEF categories 167 
were older, had lower body mass index and were more likely to be males. As well, a 168 
history of other comorbidities, a more severe presentation with lower systolic blood 169 
pressure and higher Killip class, and use of diuretics were more frequent. Typical 170 
parameters associated with HF and low LVEF, such as decreased glomerular filtration 171 
rate and lower concentrations of hemoglobin and sodium, were also found to be more 172 
common in patients with LVEF <25%. Use of pharmacotherapy according to 173 
contemporary standards was observed in the majority of patients.  174 
 175 
Rates of hospitalizations according to left ventricular ejection fraction categories 176 
As illustrated in Figure 1, the event rates for HF, MI, and non CV hospitalizations 177 
increased with decreasing LVEF and were particularly high in subjects with LVEF 178 
<25%. At two years, the absolute risk increase associated with LVEF <25% (vs 179 
LVEF >35%) was 15.5% (95% CI 13.4-17.5) for HF hospitalization, 4.7% (95% CI 180 
3.0-6.4) for MI hospitalization, and 10.4% (95% CI 8.0-12.8) for non CV 181 
hospitalization (Figure 1). The proportions of different types of hospitalizations that 182 
occurred during follow-up stratified according to LVEF categories are also provided 183 
in Supplementary Table 1. 184 
 185 
Left ventricular ejection fraction and clinical events 186 
Table 2 and 3 summarize the findings from the Fine and Grey statistical assessment of 187 
LVEF as a predictor of the various endpoints. The overall pattern from the analyses 188 
indicated that the strongest association existed between LVEF and HF hospitalization, 189 
with a more modest association to MI hospitalizations and non CV hospitalizations. In 190 
the most adjusted models that included an extensive selection of covariates (model 3), 191 
each 5-point decrease in LVEF was associated with a 15% increased risk of HF 192 
hospitalization (HR 1.15, 95% CI 1.12-1.18), a 6% increased risk of MI 193 
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hospitalization (HR 1.06, 95% CI 1.03-1.10), and a 3% increased risk of non CV 194 
hospitalization (HR 1.03, 95% CI 1.01-1.05) (Table 2). When evaluating LVEF by 195 
categories and using LVEF >35% as reference, LVEF <25 was associated with a 92% 196 
increased risk of HF hospitalization (HR 1.92, 95% CI 1.68-2.21), a 34% increased 197 
risk of MI hospitalization (HR 1.34, 95% CI 1.13-1.59), and a 18% increased risk of 198 
non CV hospitalization (HR 1.18, 95% CI 1.05-1.32) (Table 3). As depicted in the 199 
table, the increased risk for events in the LVEF 25-35% category was less distinct, but 200 
still significant for the majority of hospitalization types. The trend of LVEF being 201 
most strongly associated with HF hospitalization was also present in the less adjusted 202 
models (Table 2 and 3). Moreover, a similar pattern was observed in the exploratory 203 
assessment of the discriminative properties of LVEF, where the increase Harrell's c-204 
index and continuous net reclassification improvement at one year were found to be 205 
statistically significantly improved after addition of continuous LVEF to all models 206 
that were tested for prediction of HF and MI events (continuous net reclassification 207 
improvement on top of the most complete model 9.4, 6.3 to 12.0, p<0.0001 for HF 208 
hospitalization and 4.5, 1.5 to 6.9, p=0.013 for MI hospitalization, Supplementary 209 
Table 2 and 3).210 





This IPD meta-analysis of 19,740 high-risk acute MI individuals assessed the 212 
association between LVEF and independently adjudicated cause-specific 213 
hospitalizations. We have shown that lower LVEF was associated with various types 214 
of hospitalizations in the period following the index acute MI, including non CV 215 
hospitalizations. The absolute risk increase in non CV hospitalizations associated with 216 
LVEF<25% was 2/3 of the absolute risk increase in HF hospitalizations and twice the 217 
absolute risk increase in MI hospitalizations. On a relative scale, the association of 218 
lower LVEF with MI and non CV hospitalizations were milder than with HF 219 
hospitalizations; However, this milder association should be interpreted in light of the 220 
absolute risk of these causes of hospitalization. Lower LVEF consequently appears as 221 
an integrative marker of sicker patient status. 222 
 HF is a clinical syndrome that is defined by the presence of classical 223 
symptoms and abnormal cardiac function leading to reduced cardiac output and/or 224 
elevated intracardiac pressures at rest or during stress.21 Our finding of a strong 225 
relationship between LVEF (as surrogate of stroke volume) and HF hospitalizations 226 
during follow-up after high-risk MI is not surprising. It is also supported by the results 227 
from other investigations which have documented an increased risk of HF death 228 
and/or HF hospitalizations associated with lower LVEF in study samples of post MI 229 
or chronic HF patients.5,8,20,22 In an earlier study of long-term myocardial infarction 230 
survivors, each 1-point decrease in LVEF was associated with a 4% increased risk of 231 
a HF hospitalization.22 The strength of LVEF as an independent predictor of HF 232 
events has also been demonstrated in chronic HF patients, such as in PARADIGM-233 
HF , e e eac  5-point decrease in LVEF was associated with a 9% increased risk 234 
of HF hospitalization in multivariable models.23 Thus, as individuals in our study 235 
were high-risk acute MI patients, our finding of a 15% increased risk concord well 236 
with these prior investigations. Furthermore, the importance of identifying 237 
independent predictors of these events are additionally reinforced by an analysis of 238 
stable MI survivors demonstrating that a HF hospitalization is associated with a 239 
highly significant increased risk of death.5,22 240 
Our documentation of reduced LVEF being an independent risk factor for 241 
future MI hospitalization and non CV hospitalization in models that consider death as 242 
competing risk is novel and has, to the best of our knowledge, not been described 243 
before in this particular population. Previously published analyses of the same study 244 




sample have demonstrated a congruent pattern of results with both continuous and 245 
categorical LVEF variables being statistically significant predictors of non-HF CV 246 
and non CV mortality endpoints, which may be seen as further strengthening the 247 
confidence in the aforementioned observation.20 The mechanisms underpinning these 248 
observed relationships are likely multifactorial and there are several potential 249 
pathophysiological explanations that support an increased occurrence of new events. 250 
Patients with lower LVEF might have more complex coronary disease, and 251 
subsequent higher risk of recurrent MI. One explanation of the increased frequency of 252 
non CV hospitalizations in the lower categories may be that a poorer LV contractile 253 
function makes patients more vulnerable to transient and/or undetected pulmonary 254 
oedema. One may speculate that this could lessen the respiratory reserves needed to 255 
tackle bouts of chronic obstructive pulmonary disease or pneumonia and subsequently 256 
result in admission to hospital for these conditions. Alternatively, LVEF may just be a 257 
marker for frailty or other unknown risk factors for non CV causes that were not 258 
evaluated in the models. It is also possible that some individuals presenting with 259 
typical HF symptoms such as dyspnoea and cough, which conceivably would be more 260 
frequent in patients with reduced LVEF, were misdiagnosed with symptomatically 261 
similar conditions such as pneumonia. If so, this could contribute to the independent 262 
association that were observed between decreasing LV function and non CV 263 
hospitalizations. Nonetheless, even though the underlying pathophysiological 264 
mechanisms and the discriminative properties of LVEF for these endpoints appear 265 
less robust than for HF hospitalizations, we value the fact that particularly non CV 266 
hospitalizations occurred more frequent than previously assumed in post acute MI 267 
patients as an important finding. 268 
The strength of association on a relative scale was weaker for MI 269 
hospitalization and non CV hospitalization. However, we should keep in mind, as our 270 
group already emphasized, that the absolute scale is more relevant than the relative 271 
scale in a number of clinical settings.24,25 In the analysis reported herein, the increase 272 
in the risk of non CV hospitalizations associated with LVEF <25% was fairly similar 273 
(2/3) to the absolute risk increase in HF hospitalizations, and may consequently be 274 
considered to have significant implications. In other words, in routine practice, we 275 
should keep in mind that patients with the lowest LVEF are almost at similarly 276 
increased risk of non CV hospitalization than HF hospitalization. Whether novel 277 
interventions targeting LVEF are able to reduce the number of these types of 278 




hospitalizations following MI remains unknown and should be tested in future trials. 279 
However, as is, our results suggest that LVEF is an integrated marker of sicker 280 
patients rather than a specific HF marker. 281 
 282 
Strengths and limitations 283 
We see the independent adjudication of prospectively defined endpoints as an 284 
important strength of the present study, as it reduces the impact from differences in 285 
local practice and investigator bias thus enhancing accuracy, precision, interpretability 286 
and potential for generalizability of the results.26 The IPD meta-analysis design 287 
allowed for adequate power in assessing subgroups and facilitated adjustment of a 288 
vast number of covariates in the models.27 However, the inherent selection of patients 289 
during the inclusion process of clinical trials must be considered when considering 290 
transferability to local practice. Use of mineralocorticoid receptor antagonists, an 291 
important component of guidelines-conform HF treatment, was not part of standard 292 
care when the trials were conducted.28 Another limitation is that non-HF CV 293 
hospitalization, non CV hospitalization, and use of beta-blockers were not available 294 
from the CAPRICORN trial data, and that hemoglobin and sodium were not reported 295 
for VALIANT subjects. 296 
 297 
Conclusions 298 
In a high-risk population with complicated acute MI, LVEF was an independent 299 
predictor of all types of hospitalization. The absolute risk increase in non CV 300 
hospitalizations associated with LVEF <25% appears important as it represent 2/3 of 301 
the absolute risk increase in HF hospitalizations and twice the absolute risk increase 302 
in MI hospitalizations. Lower LVEF appears as an integrative marker of sicker patient 303 
status, associated with HF and non HF related hospitalizations.  304 
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Figure legends 446 
 447 
Figure 1 Kaplan-Meyer estimates for types of hospitalization. Curves according to 448 
different left ventricular ejection fraction categories. 449 
Table 1. Baseline characteristics according to left ventricular ejection fraction categories 
Characteristics LVEF < 25% (n=1919) 
LVEF 25-35% 
(n=10999) 
















Demography         
Age (years) 65.6 ± 11.7 64 ± 11.8 63.6 ± 11.6 < 0.0001 0.132 0.169 0.036 0.112 
Female 26.8 28.8 31.2 0.0001 0.043 0.095 0.052 0.064 
Weight (kg) 78.1 ± 15.7 79.6 ± 15.9 79.6 ± 15.8 0.0003 0.099 0.095 0.004 0.066 
BMI (kg/m²) 27.1 ± 4.7 27.6 ± 4.7 27.8 ± 4.7 < 0.0001 0.115 0.153 0.038 0.102 
Medical history         
Renal insufficiency 7.2 3.6 3.1 < 0.0001 0.161 0.186 0.025 0.124 
COPD 11.0 8.5 8.3 0.0005 0.086 0.093 0.007 0.062 
Peripheral artery disease 12.2 9.4 9.7 0.0008 0.089 0.081 0.008 0.059 
Diabetes 32.2 28.1 26.9 < 0.0001 0.088 0.115 0.027 0.076 
Hypertension 56.3 58.2 59.9 0.010 0.038 0.072 0.034 0.048 
Obesity (BMI > 30) 22.7 26.1 26.3 0.004 0.079 0.084 0.006 0.056 
Clinical         
Killip class (III-IV vs. I-II) 25.7 18.0 18.9 < 0.0001 0.188 0.166 0.022 0.125 
Systolic BP (mmHg) 118 ± 16 121 ± 16 122 ± 17 < 0.0001 0.185 0.295 0.111 0.197 
Medication use         
ACE inhibitors and/or ARB 67.2 58.1 61.2 < 0.0001 0.190 0.125 0.065 0.127 
Beta-blockers 64.2 72.5 71.5 < 0.0001 0.178 0.156 0.022 0.119 
Diuretics 65.8 48.9 49.6 < 0.0001 0.347 0.332 0.015 0.231 
Biochemistry         
eGFR (ml/min/1.73m²) 67.4 ± 21.8 70.6 ± 21.9 71.1 ± 21.3 < 0.0001 0.148 0.174 0.024 0.115 
Hemoglobin (g/dL) 13.1 ± 1.9 13.3 ± 1.7 13.4 ± 1.6 0.0003 0.098 0.152 0.054 0.102 
Sodium (mmol/L) 138.5 ± 4.2 139.1 ± 4.1 139.7 ± 3.9 < 0.0001 0.146 0.293 0.147 0.195 
LVEF         
Mean ± SD 19.8 ±  3.1 31.5 ±  3.3 42.3 ±  6.6      
Range 10 - 24.9 25 - 35 35.2 - 65      
ASMD: absolute standardized mean difference; ACE: angiotensin-converting enzyme; ARB: 
angiotensin receptor blockers; BMI: body mass index; BP: blood pressure; COPD: chronic obstructive 
pulmonary disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection 
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Figure 1A. HF hospitalization. 
  
 N total N event % event 
LVEF < 25 1919 413 21.5 
LVEF 25-35 10999 1343 12.2 




 Risk at 1 year (CI 95%) Risk at 2 years (CI 95%) 
LVEF < 25 20.0 (18.1 - 21.9) 25.7 (23.4 - 27.9) 
LVEF 25-35 10.6 (10.0 - 11.2) 13.6 (12.9 - 14.3) 
LVEF > 35 7.7 (7.0 - 8.3) 10.2 (9.4 - 11.0) 
 
 
Risk difference at 1 year 
(CI 95 %) 
Risk difference at 2 years 
(CI 95 %) 
LVEF < 25 12.4 (10.4 - 14.4) 15.5 (13.4 - 17.5) 
LVEF 25-35 2.9 (2.0 - 3.8) 3.4 (2.4 - 4.4) 
LVEF > 35 - - 
  
Figure 1
Figure 1B. MI hospitalization. 
 
 N total N event % event 
LVEF < 25 1681 191 11.4 
LVEF 25-35 10076 905 9.0 




 Risk at 1 year (CI 95%) Risk at 2 years (CI 95%) 
LVEF < 25 9.7 (8.2 - 11.2) 13.1 (11.2 - 14.9) 
LVEF 25-35 7.4 (6.9 - 8.0) 9.8 (9.2 - 10.5) 
LVEF > 35 6.1 (5.5 - 6.7) 8.4 (7.6 - 9.1) 
 
 
Risk difference at 1 year 
(CI 95 %) 
Risk difference at 2 years 
(CI 95 %) 
LVEF < 25 3.6 (2.0 - 5.2) 4.7 (3.0 - 6.4) 
LVEF 25-35 1.3 (0.5 - 2.1) 1.5 (0.5 - 2.4) 
LVEF > 35 - - 
 
  
Figure 1C. Non CV hospitalization. 
 
 N total N event % event 
LVEF < 25 1681 437 26.0 
LVEF 25-35 10076 2112 21.0 




 Risk at 1 year (CI 95%) Risk at 2 years (CI 95%) 
LVEF < 25 20.9 (18.8 - 23.0) 31.8 (29.0 - 34.4) 
LVEF 25-35 15.6 (14.9 - 16.3) 23.2 (22.3 - 24.2) 
LVEF > 35 14.2 (13.3 - 15.1) 21.3 (20.2 - 22.5) 
 
 
Risk difference at 1 year 
(CI 95 %) 
Risk difference at 2 years 
(CI 95 %) 
LVEF < 25 6.6 (4.4 - 8.9) 10.4 (8.0 - 12.8) 
LVEF 25-35 1.4 (0.2 - 2.5) 1.9 (0.5 - 3.3) 
LVEF > 35 - - 
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